Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Cyclacel Pharmaceuticals Inc
CYCCCurrent price
1.7 USD
+0.02 USD (+1.19%)
Last closed
1.68 USD
Company
www.cyclacel.com
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
2 443 644 USD
Yield for 12 month
+161.54 %
1Y
3Y
5Y
10Y
15Y
CYCC
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey. Address: 200 Connell Drive, Berkeley Heights, NJ, United States, 07922
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
11 USDP/E ratio
–Dividend Yield
–Current Year
+420 000 USD
Last Year
+373 000 USD
Current Quarter
+29 000 USD
Last Quarter
+31 000 USD
Current Year
+389 000 USD
Last Year
-32 000 USD
Current Quarter
+27 000 USD
Last Quarter
+23 000 USD
Key Figures CYCC
1 year
3 years
5 years
10 years
EBITDA
-22 464 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-99.6 %
PEG Ratio
–
Return On Equity TTM
-496.02 %
Wall Street Target Price
11 USD
Revenue TTM
449 000 USD
Book Value
-1.67 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
-455 000 USD
Earnings per share
-22.02 USD
Diluted Eps TTM
-22.02 USD
Most Recent Quarter
I 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics CYCC
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CYCC
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:15
Payout Ratio
–
Last Split Date
18.12.2023
Dividend Date
15.04.2020
Stock Valuation CYCC
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
6.0999
Price Sales TTM
5.5241
Enterprise Value EBITDA
0.0402
Price Book MRQ
3.8223
Financials CYCC
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators CYCC
For 52 weeks
1.3 USD
11.34 USD
50 Day MA
1.88 USD
Shares Short Prior Month
154 701
200 Day MA
3.18 USD
Short Ratio
0.69
Shares Short
167 309
Short Percent
12.12 %
BeatStart